The effect of digoxin on the quality of life in patients with heart failure

被引:38
作者
Lader, E
Egan, D
Hunsberger, S
Garg, R
Czajkowski, S
McSherry, F
机构
[1] NYU, Sch Med, New York, NY USA
[2] NHLBI, NIH, Bethesda, MD 20892 USA
[3] NCI, NIH, Bethesda, MD 20892 USA
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
[5] Perry Point VA Med Ctr, Perry Point, MD USA
关键词
exercise tolerance; 6-minute walk test; DIG trial;
D O I
10.1054/jcaf.2003.7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The Digitalis Investigation Group (DIG) trial was a randomized double-blind placebo-controlled study that examined the effect of digoxin on mortality in 7,788 patients with heart failure and sinus rhythm. A prespecified substudy evaluated the effect of digoxin therapy on health-related quality of life (HQOL) in a subset of these patients. Methods: Patients in the DIG trial had clinical heart failure and were randomized to either digoxin or placebo in addition to their baseline diuretic and angiotensin-converting enzyme therapy (n = 7,788). The patients in this substudy had HQCL measured using a self-administered questionnaire employing scales that measured general health, physical functioning, depression, anger, anxiety, life satisfaction, and disease specific measures. A subjective assessment by the investigator and a 6-minute walk test evaluated functional status. HQOL was measured at baseline and at the 4- and 12-month follow-up visits. Results: The baseline characteristics of the patients in the quality of life substudy (n = 589) were comparable to the remaining patients in the study (n = 7,199) by age and other clinical measures, including history of prior myocardial infarction or etiology of heart failure; heart failure was of shorter duration and the ejection fraction was slightly better than in the main trial. Within the substudy, patients receiving digoxin (n = 298) or placebo (n = 291) were also similar in baseline characteristics. There was no statistically significant difference in any HQOL measure between the digoxin and the placebo groups at baseline. At the 4-month visit, only perceived health was improved in the digoxin group. At 12 months, there was no statistically significant difference in perceived health, physical functioning, Minnesota Living with Heart Failure, depression, anxiety, anger, Ladder of Life, or the 6-minute walk between the digoxin and placebo groups. Conclusion: In this subset of the DIG population, digoxin therapy had no effect on the HQOL in patients with heart failure in sinus rhythm.
引用
收藏
页码:4 / 12
页数:9
相关论文
共 38 条
[1]  
Abernathy GT, 1996, CONTROL CLIN TRIALS, V17, P77
[2]  
American Heart Association, 2001, 2001 HEART STROK STA
[3]  
[Anonymous], 1988, JAMA, V259, P539
[4]   EXERCISE CAPACITY AND QUALITY OF LIFE IN THE TREATMENT OF HEART-FAILURE [J].
BLACKWOOD, R ;
MAYOU, RA ;
GARNHAM, JC ;
ARMSTRONG, C ;
BRYANT, B .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 48 (03) :325-332
[5]   Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect" [J].
Braunholtz, DA ;
Edwards, SJL ;
Lilford, RJ .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2001, 54 (03) :217-224
[6]   Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure [J].
Bristow, MR ;
Gilbert, EM ;
Abraham, WT ;
Adams, KF ;
Fowler, MB ;
Hershberger, RE ;
Kubo, SH ;
Narahara, KA ;
Ingersoll, H ;
Krueger, S ;
Young, S ;
Shusterman, N .
CIRCULATION, 1996, 94 (11) :2807-2816
[7]  
Cantril H., 1995, PATTERN HUMAN CONCER
[8]   EFFECT OF VASODILATOR THERAPY ON MORTALITY IN CHRONIC CONGESTIVE-HEART-FAILURE - RESULTS OF A VETERANS-ADMINISTRATION COOPERATIVE STUDY [J].
COHN, JN ;
ARCHIBALD, DG ;
ZIESCHE, S ;
FRANCIOSA, JA ;
HARSTON, WE ;
TRISTANI, FE ;
DUNKMAN, WB ;
JACOBS, W ;
FRANCIS, GS ;
FLOHR, KH ;
GOLDMAN, S ;
COBB, FR ;
SHAH, PM ;
SAUNDERS, R ;
FLETCHER, RD ;
LOEB, HS ;
HUGHES, VC ;
BAKER, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (24) :1547-1552
[9]  
COWLEY AJ, 1994, BRIT HEART J, V72, P226
[10]  
DRACUP K, 1992, J HEART LUNG TRANSPL, V11, P273